Indian stock markets witnessed a broad-based decline on April 7, primarily due to concerns about a renewed global trade war following tariff threats from US President Donald Trump. However, amid the turbulence, FMCG stocks emerged as a defensive haven, displaying relative strength even as the rest of the market saw steep corrections. In stark contrast, pharmaceutical stocks suffered heavy losses due to fears of impending tariffs on Indian drug exports to the United States.

FMCG Stocks Show Defensive Strength

The Nifty FMCG index stood out as the least impacted among sectoral indices, reflecting investor confidence in consumer staples amid macroeconomic uncertainty. Out of the 15 constituents in the FMCG pack, three stocks—Hindustan Unilever (HUL), Britannia Industries, and Godrej Consumer Products—closed in the green, posting marginal gains of up to 0.6 percent.

The resilience of FMCG stocks can be attributed to their consumer-facing business models, which are largely domestically oriented. This insulates them from international trade shocks, including tariffs and sanctions, making them attractive during volatile market conditions.

Moreover, defensive buying tends to favour FMCG during downturns as these companies sell essential goods such as food, household items, and personal care products, which continue to have steady demand irrespective of the economic climate.

Pharma Sector Faces Tariff Turbulence

While FMCG offered some shelter, the Nifty Pharma index bore the brunt of the selloff, with all 20 constituents trading in the red. Stocks like Biocon, IPCA Laboratories, Granules India, and Divi's Laboratories were among the worst hit, shedding 6 to 7 percent of their value.

The plunge in pharma stocks was largely driven by fear over US-imposed tariffs on Indian pharmaceutical imports. President Trump’s administration has floated the idea of secondary sanctions and reciprocal trade policies, which could potentially end the tax-free status Indian pharma companies currently enjoy when exporting to the US.

This poses a significant threat to the business models of Indian pharmaceutical firms, many of which rely heavily on the US market for their revenue. The US is the largest export destination for Indian pharma products, accounting for a sizable share of foreign earnings.

Trade Imbalance at the Core

Currently, Indian pharmaceutical exports to the US enter duty-free, whereas Indian imports of pharmaceutical products from the US are subject to a 10 percent tariff. This trade imbalance is what the Trump administration seeks to address through its tariff rhetoric.

Should tariffs be imposed, Indian companies might be forced to invest in setting up manufacturing operations in the US, a move that would be cost-intensive and time-consuming. Several pharma companies are adopting a wait-and-watch approach, concerned about rising operational costs and regulatory burdens in the American market.

Market Reactions Reflect Geopolitical Jitters

The broader market responded negatively to Trump’s tariff threats, fearing a renewed trade war between major economies. The implications go beyond pharma and FMCG, potentially affecting export-heavy sectors, inflation levels, and GDP growth projections.

However, defensive sectors like FMCG remain attractive in the current environment. Investors are rotating funds into stable, low-volatility stocks to safeguard against uncertain global headwinds.

Key Stock Performances on April 7

• Hindustan Unilever (HUL): Rose by 0.4%

• Britannia Industries: Gained 0.6%

• Godrej Consumer Products: Ended slightly in the green

• Biocon: Fell by 6.8%

• Divi's Laboratories: Declined by 6.5%

• Granules India & IPCA Labs: Dropped over 6%

FMCG: A Safe Haven Amidst Global Uncertainty

The Indian FMCG sector is poised to benefit from continued domestic demand, government support for rural consumption, and low export dependency. As fears of a global economic slowdown and geopolitical instability intensify, FMCG players may continue to attract safe-haven buying, especially from institutional investors.

While pharma traditionally is also a defensive bet, the sector’s international exposure, particularly to the US, is currently a liability rather than an asset due to emerging protectionist policies.

Conclusion

The April 7 market activity underscored a crucial shift in investor behaviour—away from globally exposed sectors and towards domestically insulated industries. As the US ramps up its trade pressure, Indian markets will continue to react sharply to geopolitical signals.

Going forward, FMCG may remain stable under pressure, while pharma needs policy clarity to regain investor confidence. Stakeholders in the Indian pharmaceutical space must strategically evaluate their dependence on US exports, possibly rebalancing operations to minimise future trade risks.

The Upcoming IPOs in this week and coming weeks are Aten Papers & Foam.

The Closed IPOs are  Infonative Solutions Limited, Spinaroo Commercial Limited,Retaggio Industries Limited.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in .Choice Broking FinX